NZ722375A - Diaryl macrocycles as modulators of protein kinases - Google Patents
Diaryl macrocycles as modulators of protein kinasesInfo
- Publication number
- NZ722375A NZ722375A NZ722375A NZ72237515A NZ722375A NZ 722375 A NZ722375 A NZ 722375A NZ 722375 A NZ722375 A NZ 722375A NZ 72237515 A NZ72237515 A NZ 72237515A NZ 722375 A NZ722375 A NZ 722375A
- Authority
- NZ
- New Zealand
- Prior art keywords
- modulators
- protein kinases
- macrocycles
- diaryl
- diaryl macrocycles
- Prior art date
Links
- -1 Diaryl macrocycles Chemical class 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ761094A NZ761094A (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931506P | 2014-01-24 | 2014-01-24 | |
| US201462049326P | 2014-09-11 | 2014-09-11 | |
| US201562106301P | 2015-01-22 | 2015-01-22 | |
| PCT/US2015/012597 WO2015112806A2 (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ722375A true NZ722375A (en) | 2022-11-25 |
Family
ID=53682127
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ722375A NZ722375A (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
| NZ761094A NZ761094A (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ761094A NZ761094A (en) | 2014-01-24 | 2015-01-23 | Diaryl macrocycles as modulators of protein kinases |
Country Status (35)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| EP2350071B1 (en) | 2008-10-22 | 2014-01-08 | Array Biopharma, Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| DK2918588T3 (en) | 2010-05-20 | 2017-08-28 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| DK3636649T3 (da) * | 2014-01-24 | 2024-05-21 | Turning Point Therapeutics Inc | Diarylmakrocykler som modulatorer af proteinkinaser |
| TWI767858B (zh) | 2014-11-16 | 2022-06-11 | 美商亞雷生物製藥股份有限公司 | (S)-N-(5-((R)-2-(2,5-二氟苯基)-吡咯啶-1-基)-吡唑并[1,5-a]嘧啶-3-基)-3-羥基吡咯啶-1-甲醯胺硫酸氫鹽結晶型 |
| US10758525B2 (en) | 2015-01-22 | 2020-09-01 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds |
| AU2016270803A1 (en) | 2015-06-01 | 2018-01-04 | Loxo Oncology, Inc. | Methods of diagnosing and treating cancer |
| CA2989327A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| HRP20240780T1 (hr) | 2015-07-06 | 2024-09-13 | Turning Point Therapeutics, Inc. | Polimorf diaril makrocikla |
| PT3322706T (pt) | 2015-07-16 | 2021-03-08 | Array Biopharma Inc | Compostos de pirazolo[1,5-a]piridina substituídos como inibidores da quinase do ret |
| EP3733187B1 (en) * | 2015-07-21 | 2024-10-16 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
| SG11201803438XA (en) | 2015-10-26 | 2018-05-30 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| US11278521B2 (en) | 2015-12-15 | 2022-03-22 | University Of South Florida | GAS5 binding compounds, formulations, and uses thereof |
| PE20181888A1 (es) | 2016-04-04 | 2018-12-11 | Loxo Oncology Inc | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| JP7057343B2 (ja) | 2016-04-04 | 2022-04-19 | ロクソ オンコロジー， インコーポレイテッド | 小児癌の処置方法 |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| HUE053643T2 (hu) | 2016-05-18 | 2021-07-28 | Loxo Oncology Inc | (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése |
| BR112019001607A2 (pt) * | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | inibidores macrocíclicos de quinases |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| CN107586796B (zh) * | 2017-07-20 | 2021-08-06 | 暨明医药科技（苏州）有限公司 | (r)-2-(1-氨基乙基)-4-氟苯酚的合成方法 |
| PT3658148T (pt) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| CA3080157A1 (en) | 2017-10-26 | 2019-05-02 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| CN109516999B (zh) * | 2017-11-01 | 2021-08-17 | 郑州泰基鸿诺医药股份有限公司 | 用作蛋白质激酶调节剂的化合物及其应用 |
| CA3081790C (en) | 2017-11-10 | 2023-03-07 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as trk kinase inhibitors and uses thereof |
| EP3728270A4 (en) | 2017-12-19 | 2021-06-23 | Turning Point Therapeutics, Inc. | MACROCYCLIC KINASE INHIBITORS AND THEIR USES |
| KR102814342B1 (ko) | 2017-12-19 | 2025-05-29 | 터닝 포인트 테라퓨틱스, 인크. | 질병 치료용 대환식 화합물 |
| US11453672B2 (en) | 2017-12-22 | 2022-09-27 | Shenzhen Targetrx, Inc. | Substituted pyrazolo[1,5-a]pyrimidines as tropomyosin receptor kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
| CN109575025B (zh) * | 2018-01-23 | 2020-09-11 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
| CN111511749B (zh) * | 2018-01-30 | 2022-02-08 | 上海吉倍生物技术有限公司 | 具有大环分子结构的化合物及其用途 |
| CN110156813B (zh) * | 2018-02-13 | 2023-07-25 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| US11555042B2 (en) * | 2018-03-28 | 2023-01-17 | Fochon Biosciences, Ltd. | Macrocyclic compounds as TRK kinases inhibitors |
| US20210023086A1 (en) | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| CN110386944B (zh) * | 2018-04-16 | 2021-10-29 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的二(杂)芳基大环化合物 |
| WO2019206069A1 (zh) * | 2018-04-25 | 2019-10-31 | 北京普祺医药科技有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| CN111918868B (zh) * | 2018-05-04 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 作为蛋白激酶调节剂的二芳基大环化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| CN110950889B (zh) * | 2018-09-27 | 2022-04-05 | 北京赛林泰医药技术有限公司 | 一种多靶点激酶抑制剂及其制备方法和用途 |
| CN112955453B (zh) * | 2018-09-29 | 2022-04-19 | 山东绿叶制药有限公司 | 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 |
| MX2021004538A (es) | 2018-10-22 | 2021-09-10 | Esker Therapeutics Inc | Inhibidores de tyk2 y sus usos. |
| CN111171049B (zh) * | 2018-11-09 | 2021-06-04 | 山东轩竹医药科技有限公司 | 酪氨酸激酶抑制剂及其用途 |
| AU2019375825B2 (en) * | 2018-11-09 | 2022-09-15 | Shandong Xuanzhu Pharma Co., Ltd. | Macrocyclic tyrosine kinase inhibitor and uses thereof |
| WO2020106685A1 (en) * | 2018-11-19 | 2020-05-28 | Dana-Farber Cancer Institute, Inc. | Macrocyclic inhibitors of dyrk1a |
| EP3898615A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| US12180207B2 (en) | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| CN111592541B (zh) * | 2019-02-21 | 2021-09-10 | 山东轩竹医药科技有限公司 | 大环类激酶抑制剂及其用途 |
| WO2020185755A1 (en) * | 2019-03-11 | 2020-09-17 | Fronthera U.S. Pharmaceuticals Llc | Tyk2 inhibitors and uses thereof |
| MX2021011723A (es) * | 2019-03-26 | 2021-10-22 | Ventyx Biosciences Inc | Ligandos de pseudocinasa tyk2. |
| CN113727984B (zh) * | 2019-05-21 | 2024-03-15 | 浙江海正药业股份有限公司 | 大环类衍生物、及其制备方法和用途 |
| WO2020257165A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for use in treating disease |
| WO2020257189A1 (en) * | 2019-06-19 | 2020-12-24 | Turning Point Therapeutics, Inc. | Macrocycles for treating disease |
| PE20220135A1 (es) * | 2019-06-19 | 2022-01-27 | Turning Point Therapeutics Inc | Polimorfos de un inhibidor de cinasas macrociclicas |
| CN113773335B (zh) * | 2019-06-21 | 2024-12-03 | 成都海博为药业有限公司 | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 |
| MX2021015770A (es) * | 2019-06-21 | 2022-04-12 | Janssen Pharmaceutica Nv | Inhibidores macrociclicos de mcl-1. |
| JP2022540678A (ja) | 2019-07-16 | 2022-09-16 | マイオカーディア，インク | （ｒ）－４－（１－（（３－（ジフルオロメチル）－１－メチル－１ｈ－ピラゾール－４－イル）スルホニル）－１－フルオロエチル）－ｎ－（イソキサゾール－３－イル）ピペリジン－１－カルボキシアミドの多形体 |
| WO2021027503A1 (zh) * | 2019-08-12 | 2021-02-18 | 罗欣药业(上海)有限公司 | 三环类化合物、其制备方法、中间体及应用 |
| WO2021063276A1 (zh) * | 2019-09-30 | 2021-04-08 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
| CN114901286B (zh) | 2019-11-27 | 2024-05-10 | 特普医药公司 | 涉及二芳基巨环化合物的组合疗法 |
| TW202133856A (zh) | 2019-11-27 | 2021-09-16 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| KR20220133869A (ko) * | 2019-12-03 | 2022-10-05 | 터닝 포인트 테라퓨틱스, 인크. | 질환 치료에 사용하기 위한 거대고리 |
| EP4069369A4 (en) | 2019-12-06 | 2024-02-14 | Schrödinger, Inc. | CYCLIC COMPOUNDS AND METHODS OF USE THEREOF |
| CN113045587A (zh) * | 2019-12-27 | 2021-06-29 | 成都倍特药业股份有限公司 | 一种大环结构化合物的晶型及其制备方法 |
| PH12022551523A1 (en) | 2019-12-27 | 2024-01-29 | SchraDinger Inc | Cyclic compounds and methods of using same |
| CN113135938B (zh) * | 2020-01-19 | 2022-06-14 | 山东轩竹医药科技有限公司 | 取代的大环类酪氨酸激酶抑制剂及其用途 |
| KR20230022151A (ko) * | 2020-03-02 | 2023-02-14 | 터닝 포인트 테라퓨틱스, 인크. | 거대고리 화합물의 치료 용도 |
| CR20220559A (es) | 2020-05-04 | 2023-08-18 | Vigil Neuroscience Inc | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso |
| JP7495035B2 (ja) * | 2020-05-08 | 2024-06-04 | シュエンジュウ バイオファーマシューティカル カンパニー リミテッド | 大環類チロシンキナーゼ阻害剤の結晶形及びその製造方法 |
| WO2021244609A1 (zh) * | 2020-06-04 | 2021-12-09 | 成都倍特药业股份有限公司 | 具有大环结构的化合物及其用途 |
| IL299732A (en) * | 2020-07-10 | 2023-03-01 | Blossomhill Therapeutics Inc | Macrocycles and their use |
| JP2023541047A (ja) | 2020-09-10 | 2023-09-27 | シュレーディンガー， インコーポレイテッド | がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤 |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| WO2022182845A1 (en) * | 2021-02-25 | 2022-09-01 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN113754657B (zh) * | 2021-09-22 | 2023-01-17 | 广州白云山医药集团股份有限公司白云山制药总厂 | 大环类化合物的晶型及其制备方法和应用 |
| WO2023078267A1 (zh) * | 2021-11-02 | 2023-05-11 | 赛诺哈勃药业（成都）有限公司 | 作为蛋白激酶调节剂的含氨基大环化合物 |
| CN116514813A (zh) * | 2021-12-31 | 2023-08-01 | 轩竹生物科技股份有限公司 | 酪氨酸激酶抑制剂及其中间体的制备方法 |
| IL314070A (en) * | 2022-01-05 | 2024-09-01 | Blossomhill Therapeutics Inc | Macrocyclic compounds and use as kinase inhibitors |
| CN115746023B (zh) * | 2022-10-27 | 2024-08-09 | 复旦大学 | 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| WO2025217347A2 (en) | 2024-04-11 | 2025-10-16 | Bristol-Myers Squibb Company | Process of preparing repotrectinib |
| WO2025235733A1 (en) * | 2024-05-09 | 2025-11-13 | Blossomhill Therapeutics, Inc. | Bis-bicycloheteroaryl macrocycles and their use |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4838925A (en) | 1986-04-25 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| DE3861031D1 (de) | 1987-03-07 | 1990-12-20 | Bayer Ag | Verfahren zur herstellung von 5-amino-4,6-dihalogenpyridinen. |
| AU679053B2 (en) | 1993-03-25 | 1997-06-19 | Pharmacia & Upjohn Company | Indoletetralins having dopaminergic activity |
| RU2147304C1 (ru) | 1993-12-07 | 2000-04-10 | Эли Лилли Энд Компани | Бис-индолмалеимидные макроциклические производные, способ их получения (варианты) и фармацевтическая композиция |
| FR2746309B1 (fr) | 1996-03-22 | 1998-04-17 | Oreal | Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture |
| GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| FR2793791B1 (fr) | 1999-05-19 | 2002-01-25 | Univ Paris 7 Denis Diderot | Nouveaux composes inhibiteurs specifiques de phospholipases a2 |
| KR100539139B1 (ko) | 2000-07-31 | 2005-12-26 | 에프. 호프만-라 로슈 아게 | 피페라진 유도체 |
| AU2737102A (en) | 2000-12-08 | 2002-06-18 | Ortho Mcneil Pharm Inc | Macroheterocylic compounds useful as kinase inhibitors |
| CA2441080A1 (en) | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
| AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
| US7970766B1 (en) | 2007-07-23 | 2011-06-28 | Google Inc. | Entity type assignment |
| MX2011002470A (es) | 2008-09-08 | 2011-04-05 | Merck Patent Gmbh | Pirimidinas macrociclicas como inhibidores de aurora cinasa. |
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| EP2350071B1 (en) | 2008-10-22 | 2014-01-08 | Array Biopharma, Inc. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| CA2740792C (en) | 2008-10-31 | 2016-06-21 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| WO2010063487A1 (en) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| WO2010086040A1 (en) | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| US20110029480A1 (en) * | 2009-08-03 | 2011-02-03 | IntelliCubes, Inc. | Method of Compiling Multiple Data Sources into One Dataset |
| NZ598766A (en) | 2009-10-13 | 2013-09-27 | Elanco Animal Health Ireland | Macrocyclic integrase inhibitors |
| EP2509980A1 (en) | 2009-12-07 | 2012-10-17 | Boehringer Ingelheim International GmbH | Heterocyclic compounds containing an indole core |
| US9073926B2 (en) | 2009-12-07 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| DK2918588T3 (en) | 2010-05-20 | 2017-08-28 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012075393A2 (en) | 2010-12-02 | 2012-06-07 | President And Fellows Of Harvard College | Activators of proteasomal degradation and uses thereof |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| AU2012299218A1 (en) | 2011-08-19 | 2014-02-20 | Merck Sharp & Dohme Corp. | Crystal forms of a HCV protease inhibitor |
| WO2013045702A2 (en) | 2011-09-29 | 2013-04-04 | L'oreal | Dye composition comprising a non-glycosyl iridoid compound and a specific nucleophile or an amino or thio polymer, dyeing process, and device therefor |
| WO2013045701A2 (en) | 2011-09-29 | 2013-04-04 | L'oreal | Dyeing process using a composition comprising a glycosyl iridoid compound and a nucleophile or an amino or thio polymer, composition and devices therefor |
| GB2495134B (en) | 2011-09-30 | 2014-06-11 | Tridonic Uk Ltd | Power supply apparatus |
| CN103930427B (zh) | 2011-09-30 | 2016-03-09 | 昂科迪塞恩股份有限公司 | 大环flt3激酶抑制剂 |
| ES2627347T3 (es) | 2011-10-20 | 2017-07-27 | Glaxosmithkline Llc | Aza-heterociclos bicíclicos sustituidos y análogos como moduladores de sirtuina |
| ME02630B (me) | 2012-03-06 | 2017-06-20 | Pfizer | Makrociklički derivati, namijenjeni liječenju proliferativnih bolesti |
| PT2834243T (pt) | 2012-03-09 | 2018-08-01 | Lexicon Pharmaceuticals Inc | Compostos à base de pirazolo[1,5-a]pirimidina, composições que os compreendem e métodos para a sua utilização |
| US8969565B2 (en) * | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| EP2645540A1 (de) | 2012-03-28 | 2013-10-02 | Siemens Aktiengesellschaft | Glimmschutzwerkstoff für eine elektrische Maschine |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| JP2016506921A (ja) | 2013-01-30 | 2016-03-07 | バイエル ファーマ アクチエンゲゼルシャフト | アミノ置換イソチアゾール |
| CN105358534A (zh) | 2013-04-23 | 2016-02-24 | 斯洛文尼亚莱柯制药股份有限公司 | 8-氯-1-甲基-苯并[d]吖庚因的新合成方法、新的中间体及其生产方法 |
| US20160159808A1 (en) | 2013-07-24 | 2016-06-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2015073267A1 (en) | 2013-11-15 | 2015-05-21 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| DK3636649T3 (da) | 2014-01-24 | 2024-05-21 | Turning Point Therapeutics Inc | Diarylmakrocykler som modulatorer af proteinkinaser |
| WO2016070241A1 (en) | 2014-11-03 | 2016-05-12 | Ctxt Pty Ltd | Triazine compounds, compositions and synthesis |
| AU2015365587B2 (en) | 2014-12-15 | 2020-07-23 | Cmg Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as TRK inhibitors |
| CN107531666A (zh) | 2015-02-20 | 2018-01-02 | 里格尔药品股份有限公司 | Gdf‑8抑制剂 |
| WO2016144846A1 (en) | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| US10155765B2 (en) | 2015-03-12 | 2018-12-18 | Merck Sharp & Dohme Corp. | Carboxamide inhibitors of IRAK4 activity |
| WO2016177658A1 (en) | 2015-05-05 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| CN108289610A (zh) | 2015-06-29 | 2018-07-17 | Q-科雷医疗有限公司 | 用于感测和分析医疗装置的导管内的流体和其中的气泡的特性的方法、电路、装置、组件、系统和相关联的计算机可执行代码 |
| CA2989327A1 (en) | 2015-07-02 | 2017-01-05 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| HRP20240780T1 (hr) | 2015-07-06 | 2024-09-13 | Turning Point Therapeutics, Inc. | Polimorf diaril makrocikla |
| EP3733187B1 (en) | 2015-07-21 | 2024-10-16 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycle and use thereof in the treatment of cancer |
| SG11201803438XA (en) | 2015-10-26 | 2018-05-30 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| AU2017228385B2 (en) | 2016-03-04 | 2021-11-04 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| BR112019001607A2 (pt) | 2016-07-28 | 2019-04-30 | Tp Therapeutics, Inc. | inibidores macrocíclicos de quinases |
| WO2018112027A1 (en) | 2016-12-14 | 2018-06-21 | Development Center For Biotechnology | Antibody-drug conjugates and uses thereof |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| PT3658148T (pt) | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
-
2015
- 2015-01-23 DK DK19212110.1T patent/DK3636649T3/da active
- 2015-01-23 HU HUE19212110A patent/HUE066590T2/hu unknown
- 2015-01-23 US US18/147,888 patent/USRE50634E1/en active Active
- 2015-01-23 EA EA201691492A patent/EA031863B1/ru active IP Right Revival
- 2015-01-23 JP JP2016566857A patent/JP6490713B2/ja active Active
- 2015-01-23 CN CN201910549748.XA patent/CN110317214B/zh active Active
- 2015-01-23 AU AU2015209239A patent/AU2015209239B2/en active Active
- 2015-01-23 FI FIEP19212110.1T patent/FI3636649T3/fi active
- 2015-01-23 PL PL15740510T patent/PL3097107T3/pl unknown
- 2015-01-23 SM SM20240175T patent/SMT202400175T1/it unknown
- 2015-01-23 EA EA201892241A patent/EA201892241A1/ru unknown
- 2015-01-23 PT PT192121101T patent/PT3636649T/pt unknown
- 2015-01-23 HR HRP20221518TT patent/HRP20221518T1/hr unknown
- 2015-01-23 LT LTEP15740510.1T patent/LT3097107T/lt unknown
- 2015-01-23 WO PCT/US2015/012597 patent/WO2015112806A2/en not_active Ceased
- 2015-01-23 NZ NZ722375A patent/NZ722375A/en unknown
- 2015-01-23 EP EP19169041.1A patent/EP3572416B1/en active Active
- 2015-01-23 NZ NZ761094A patent/NZ761094A/en unknown
- 2015-01-23 DK DK15740510.1T patent/DK3097107T3/da active
- 2015-01-23 SM SM20190388T patent/SMT201900388T1/it unknown
- 2015-01-23 SG SG11201605929RA patent/SG11201605929RA/en unknown
- 2015-01-23 ES ES19212110T patent/ES2976459T3/es active Active
- 2015-01-23 SI SI201530810T patent/SI3097107T1/sl unknown
- 2015-01-23 KR KR1020167020188A patent/KR102402179B1/ko active Active
- 2015-01-23 LT LTEP19169041.1T patent/LT3572416T/lt unknown
- 2015-01-23 CN CN201910549014.1A patent/CN110317213B/zh active Active
- 2015-01-23 HR HRP20191283TT patent/HRP20191283T1/hr unknown
- 2015-01-23 HR HRP20240503TT patent/HRP20240503T1/hr unknown
- 2015-01-23 EP EP19212106.9A patent/EP3636648A1/en not_active Withdrawn
- 2015-01-23 SM SM20230008T patent/SMT202300008T1/it unknown
- 2015-01-23 ES ES15740510T patent/ES2735729T3/es active Active
- 2015-01-23 PE PE2016000959A patent/PE20160931A1/es unknown
- 2015-01-23 LT LTEP19212110.1T patent/LT3636649T/lt unknown
- 2015-01-23 RS RS20190900A patent/RS59059B1/sr unknown
- 2015-01-23 AP AP2016009383A patent/AP2016009383A0/en unknown
- 2015-01-23 MX MX2016009588A patent/MX2016009588A/es active IP Right Grant
- 2015-01-23 CA CA2936079A patent/CA2936079C/en active Active
- 2015-01-23 PT PT15740510T patent/PT3097107T/pt unknown
- 2015-01-23 PL PL19212110.1T patent/PL3636649T3/pl unknown
- 2015-01-23 SI SI201531908T patent/SI3572416T1/sl unknown
- 2015-01-23 SG SG10202000191YA patent/SG10202000191YA/en unknown
- 2015-01-23 RS RS20240447A patent/RS65417B1/sr unknown
- 2015-01-23 RS RS20221161A patent/RS63829B1/sr unknown
- 2015-01-23 EP EP19212110.1A patent/EP3636649B1/en active Active
- 2015-01-23 CN CN201580005705.5A patent/CN106170289B/zh active Active
- 2015-01-23 HU HUE19169041A patent/HUE060554T2/hu unknown
- 2015-01-23 EP EP23220719.1A patent/EP4338739A3/en active Pending
- 2015-01-23 PT PT191690411T patent/PT3572416T/pt unknown
- 2015-01-23 UA UAA201608991A patent/UA121206C2/uk unknown
- 2015-01-23 HU HUE15740510A patent/HUE045208T2/hu unknown
- 2015-01-23 SI SI201531994T patent/SI3636649T1/sl unknown
- 2015-01-23 US US15/113,583 patent/US9714258B2/en not_active Ceased
- 2015-01-23 EP EP19212126.7A patent/EP3636650A1/en not_active Withdrawn
- 2015-01-23 DK DK19169041.1T patent/DK3572416T3/da active
- 2015-01-23 MY MYPI2016001385A patent/MY193524A/en unknown
- 2015-01-23 PL PL19169041.1T patent/PL3572416T3/pl unknown
- 2015-01-23 EP EP15740510.1A patent/EP3097107B1/en active Active
- 2015-01-23 MX MX2020001360A patent/MX392904B/es unknown
- 2015-01-23 ES ES19169041T patent/ES2933350T3/es active Active
-
2016
- 2016-07-07 ZA ZA2016/04654A patent/ZA201604654B/en unknown
- 2016-07-20 IL IL246860A patent/IL246860B/en active IP Right Grant
- 2016-07-22 CL CL2016001876A patent/CL2016001876A1/es unknown
- 2016-07-25 PH PH12016501463A patent/PH12016501463A1/en unknown
-
2017
- 2017-05-31 US US15/609,962 patent/US10246466B2/en active Active
-
2018
- 2018-11-29 US US16/204,566 patent/US10618912B2/en active Active
-
2019
- 2019-02-27 JP JP2019034652A patent/JP2019104748A/ja not_active Withdrawn
- 2019-07-17 CY CY20191100764T patent/CY1121850T1/el unknown
- 2019-08-21 IL IL268820A patent/IL268820B/en unknown
- 2019-12-10 AU AU2019279951A patent/AU2019279951B2/en active Active
-
2020
- 2020-02-21 US US16/797,866 patent/US20200216465A1/en not_active Abandoned
- 2020-07-06 ZA ZA2020/04100A patent/ZA202004100B/en unknown
-
2021
- 2021-01-07 JP JP2021001588A patent/JP2021063121A/ja active Pending
- 2021-09-27 US US17/485,942 patent/US20220112213A1/en not_active Abandoned
-
2022
- 2022-07-08 JP JP2022110613A patent/JP7356546B2/ja active Active
-
2023
- 2023-07-28 US US18/227,561 patent/US12404281B2/en active Active
- 2023-09-22 JP JP2023158350A patent/JP2023179539A/ja not_active Ceased
-
2025
- 2025-03-12 NL NL301322C patent/NL301322I2/nl unknown
- 2025-03-13 NO NO2025015C patent/NO2025015I1/no unknown
- 2025-03-20 FI FIC20250015C patent/FIC20250015I1/fi unknown
- 2025-03-20 HU HUS2500016C patent/HUS2500016I1/hu unknown
- 2025-04-08 LT LTPA2025513C patent/LTPA2025513I1/lt unknown
- 2025-04-09 FR FR25C1013C patent/FR25C1013I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004100B (en) | Diaryl macrocycles as modulators of protein kinases | |
| MX2017017097A (es) | Macrociclos diarílicos quirales como moduladores de proteínas quinasas. | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| PH12016501139A1 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12019501079A1 (en) | Magl inhibitors | |
| EA033374B9 (ru) | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения | |
| SG10201810879VA (en) | Pharmaceutical compounds | |
| MX2022001310A (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX2020004476A (es) | Compuestos piridinicos de pladienolida y metodos de uso. | |
| TW201613935A (en) | Tricyclic heterocycles as BET protein inhibitors | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX395492B (es) | Usos terapeuticos de l-4 cloroquinurenina. | |
| SG10201908881PA (en) | Fused bicyclic compounds for the treatment of disease | |
| IN2013MU03118A (cg-RX-API-DMAC7.html) | ||
| TW201612183A (en) | Diaryl macrocycles as modulators of protein kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2025 BY CPA GLOBAL Effective date: 20231207 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 23 JAN 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241212 |